Table 3.
Surgery, pathologic response and survival outcomes.
| Variables (%) | All Patients (N=34) | Pembrolizumab (N=20) | Camrelizumab (N=14) |
|---|---|---|---|
| Operative duration, mean (SD), min | 211 (47) | 204 (40) | 222 (55) |
| Estimated blood loss, mean (SD), mL | 144 (126) | 144 (126) | 144 (127) |
| Postoperative hospital stay, median (IQR), day | 12 (11-17) | 13 (11-23) | 12 (10-13) |
| Completeness of Resection | |||
| R0 | 32 (94.1%) | 19 (95%) | 13 (92.9%) |
| R1 | 2 (5.9%) | 1 (5%) | 1 (7.1%) |
| Lymph nodes resected, median (IQR), No | 30 (25-38) | 31 (25-37) | 27 (23-37) |
| Complete response of primary tumor | 11 (32.4%) | 6 (30%) | 5 (35.7%) |
| TRG1 | 8 (23.4) | 4 (20) | 4 (28.6) |
| TRG | |||
| 1 | 8 (23.5%) | 4 (20%) | 4 (28.6%) |
| 2 | 3 (8.8%) | 2 (10%) | 1 (7.1%) |
| 3 | 7 (20.6) | 5 (25%) | 2 (14.3%) |
| 4 | 16 (47.1%) | 9 (45%) | 7 (50%) |
| ypT | |||
| 0 | 11 (32.4%) | 6 (30%) | 5 (35.7%) |
| 1 | 6 (17.6%) | 5 (25%) | 1 (7.2%) |
| 2 | 5 (14.7%) | 3 (15%) | 2 (14.2%) |
| 3 | 12 (35.3%) | 6 (30) | 6 (42.9%) |
| ypN+ | 19 (55.9%) | 11 (55%) | 8 (57%) |
| ypStage | |||
| I | 13 (38.2%) | 7 (35%) | 6 (42.9%) |
| II | 2 (5.9%) | 5 2(10%) | 0 |
| III | 12 (35.3%) | 6 (30%) | 6 (42.9) |
| IV | 7 (20.6%) | 5 (25%) | 2 (14.2%) |
| 1-year relapse events | 7 (20.6%) | 5 (25%) | 2 (14.2%) |
| 1-year RFS,% (95%CI) | 77.8 (64.2-94.2) | 72.7 (54.5-97) | 85.7 (69.2-100) |
IQR, interquartile range; pCR, pathological complete response; defined as no evidence of residual viable tumor cells in the resected primary tumor and lymph nodes. TRG, tumor regression grade, based on two parameters of histomorphologic tumor regression and lymph node status (ypN) (28). RFS, relapse-free survival.